Health-tech company Unexa Korea (CEO Jungkwon Kim) announced that it has joined the Society for Immunotherapy of Cancer (SITC) as a member.
SITC is one of the leading international academic organizations in the field of cancer immunotherapy, bringing together immunology researchers, clinicians, and professionals from the global biotechnology and pharmaceutical industries. The society is known for sharing the latest scientific findings and clinical data in immunotherapy and immunology through annual international conferences and research presentations.
Through this membership, Unexa Korea said it has secured a channel to continuously access global research trends and academic insights in immunology.
A company representative stated, “Understanding scientific data and research developments is a key foundation for competitiveness in the healthcare industry. Through our participation in SITC, we plan to monitor global academic trends and reflect them in our long-term business strategy.”
Unexa Korea is a health-tech company preparing a health supplement distribution business based on its IT-driven platform capabilities. The company has recently been expanding its participation in external academic networks to strengthen access to biotechnology and research-based information.
Industry observers note that it is relatively uncommon for a network-based healthcare company to join an international immuno-oncology society, viewing the move as meaningful in terms of improving access to academic information and tracking global research trends.
